Astrup, Arne

Arne Astrup is a Danish professor of human biology at Maastricht University Medical Centre in the Netherlands. He has dedicated his research to understanding the mechanisms behind obesity and developing effective weight loss interventions. His work includes studies on genome-wide associations for weight loss, focusing on two large low-caloric diet interventions: the Canadian Optifast900 meal replacement program and the DiOGenes clinical trial. Astrup's research has led to the identification of a weight loss locus on chromosome 8p11 and provided evidence for NKX6.3 as a potential functional candidate gene.

Biography:  https://www.nature.com/articles/s41467-019-08492-8

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1: A Game Changer in Obesity Therapy and Beyond

GLP-1: A Game Changer in Obesity Therapy and Beyond

Broke On: Saturday, 15 June 2024 GLP-1, a satiety hormone discovered in groundbreaking research, shows promise for obesity therapy and type 2 diabetes remission. GLP-1 drugs have led to weight loss and improved cardiovascular health, despite some side effects. Ongoing research aims to enhance their efficacy and expand their applications beyond obesity.